Covidien launches hernia repair device; Teleflex gets U.S. Army grant;

Medical Device News

@FierceMedDev: IPOs: Sientra goes for $75M, while Nevro nerves up for $100M. Report | Follow @FierceMedDev

@VarunSaxena2: Here's my pernicious article. Read it are your own risk. ICYMI yesterday | Follow @VarunSaxena2

@EmilyWFierce: Find out which companies struck gold in the pharma M&A frenzy in FiercePharma's latest special report. Report | Follow @EmilyWFierce

> Ortho-Clinical Diagnostics, makers of in vitro diagnostic products, received a CE mark for the Ortho Vision Analyzer, an interactive and fully automated analyzer for transfusion medicine laboratories. Release

> Covidien ($COV) launched ReliaTack, a laparoscopic hernia repair device with 65-degree articulation that provides surgeons with greater access to weak spots within the abdominal wall. Release

> Teleflex, a medical device company concentrating on critical care and surgery, was awarded $2.1 million in a research grant from the U.S. Army's Telemedicine and Advanced Technology Research Center (TATRC) to develop an anti-biofilm medical device. Release

> Leica Biosystems, an anatomical pathology solutions and cancer diagnostics company within Danaher ($DHR), signed an agreement to acquire Devicor, a breast biopsy procedures device player. Release

Biotech News

@FierceBiotech: $AMGN, $SNY and Ono band together for open-source R&D. Article | Follow @FierceBiotech

@JohnCFierce: Amgen adds up to 1,100 new job cuts to its global restructuring plan - Wall Street loves it, shares up 5%. News | Follow @JohnCFierce

@DamianFierce: $RNA CEO on $SRPT's setback: "We are all in this together." More from CNBC | Follow @DamianFierce

@EmilyMFierce: Salk's 100th: Anti-Vaccination Would Trouble Polio Hero. More from LiveScience | Follow @EmilyMFierce

> Novartis chief Jimenez predicts 'multi-blockbuster' success for star heart drug. Article

> Advent joins the parade of new biotech funds with $235M war chest. Item

> Receptos' lead drug scores another promising PhII--this time for ulcerative colitis. News

> Bristol-Myers nabs a HER2 cancer drug in $475M option deal with F-star. Report

Pharma News

@FiercePharma: Tops in FierceAnimalHealth: Lilly divests U.S. animal health assets to Virbac ahead of Novartis deal. Story | Follow @FiercePharma

@EricPFierce: Ranbaxy's New Jersey plant comes through for drugmaker. More | Follow @EricPFierce

@CarlyHFierce: Our newest special report is live! Pharma's top 10 M&A deals of H1 2014. Feature | Follow @CarlyHFierce

> Big relief for Lilly, Boehringer as judge slashes $9B Actos award by 99%. Report

> Pfizer beats the Street's Q3 expectations but stays mum on AZ deal. Article

> Novartis gets 4% sales lift as 'growth products' make good on their label. Story

> Looming trouble in Sanofi's diabetes biz turns up the heat on CEO. More

Biotech Research News

> Government halts research on dangerous airborne pathogens. Item

> Toxin-producing stem cells designed to kill brain cell tumors. Report

> Brain cells reprogrammed from skin cells offer treatment hope for Huntington's. Story

> Case Western, Janssen, Oncodesign scientists ID anti-inflammatory compounds. More

> Protein discovery could help kill stubborn latent HIV. Article

Pharma Manufacturing News

> Australia's CSL gets three Novartis vaccine plants in $275M deal. News

> Ranbaxy's New Jersey plant comes through for drugmaker. Item

> Hikma gets FDA warning letter for plant in Portugal. More

> Fujifilm adding Texas-based vaccine specialist to its fold. Story

> U.S. Attorney subpoenas Novo for info on Denmark plant. Article

Suggested Articles

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.

Flatiron has hired a new chief medical officer as it looks to push on under its new parent in the world of electronic health records and real-world data.